Skip to main content
Erschienen in: Journal of Experimental & Clinical Cancer Research 1/2022

Open Access 01.12.2022 | Retraction Note

Retraction Note: Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells

verfasst von: Dong-Mei Wu, Zi-Hui Zheng, Ying-Bo Zhang, Shao-Hua Fan, Zi-Feng Zhang, Yong-Jian Wang, Yuan-Lin Zheng, Jun Lu

Erschienen in: Journal of Experimental & Clinical Cancer Research | Ausgabe 1/2022

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13046-019-1239-3
Dong-Mei Wu and Zi-Hui Zheng contributed equally to this work.
Retraction Note: J Exp Clin Cancer Res 38, 237 (2019)
https://doi.org/10.1186/s13046-019-1239-3
The Editor-in-Chief has retracted this article. After publication, concerns were raised regarding the data presented in the article. Specifically:
  • In Fig. 4j, the western blot bands representing two different cell lines appear highly similar.
  • In Figs. 4n, 5c, 6b and 6c, the western blot backgrounds appear inconsistent.
  • In Fig. 6d, the images representing Huh7-Blank and HepG2-NC groups appear to contain overlap.
Additionally, the L02 and SMMC-7721 cell lines used in Fig. 1c have been reported to be contaminated with HeLa cells. The authors have been unable to address the above concerns and have stated that these data were obtained from a third party. Furthermore, the authors have been unable to provide evidence of the Ethics Committee approval for the animal study.
The Editor-in-Chief therefore no longer has confidence in the data presented and the conclusions of the article.
Dong-Mei Wu, Zi-Hui Zheng, Shao-Hua Fan, Zi-Feng Zhang, Yong-Jian Wang, Yuan-Lin Zheng and Jun Lu have not explicitly stated whether they agree to this retraction notice. Ying-Bo Zhang has not responded to any correspondence from the editor or publisher about this retraction.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Retraction Note: Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells
verfasst von
Dong-Mei Wu
Zi-Hui Zheng
Ying-Bo Zhang
Shao-Hua Fan
Zi-Feng Zhang
Yong-Jian Wang
Yuan-Lin Zheng
Jun Lu
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
Journal of Experimental & Clinical Cancer Research / Ausgabe 1/2022
Elektronische ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-022-02347-9

Weitere Artikel der Ausgabe 1/2022

Journal of Experimental & Clinical Cancer Research 1/2022 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.